Skip to main content

Table 3 Median (IQR) serum values of Klotho, FGF19 and FGF21 in relation to the occurrence of metabolic syndrome and its components as well as insulin resistance and impaired glucose tolerance

From: Klotho and fibroblast growth factors 19 and 21 serum concentrations in children and adolescents with normal body weight and obesity and their associations with metabolic parameters

 

Condition present

Condition absent

P value

Klotho

 Central obesity (N = 116)

156.4 (89.6 to 350.9)

118.5 (48.4 to 177.5)

0.0275

 Low HDL (N = 32)

156.4 (92.4 to 266.7)

134.4 (75.5 to 335.8)

0.8202

 High TG (N = 23)

134.2 (90.7 to 321.1)

140.3 (75.5 to 313.0)

0.5620

 Hypertension (N = 63)

157.5 (90.2 to 321.1)

136.0 (63.9 to 313.0)

0.1975

 Metabolic syndrome (N = 18)

172.7 (123.0 to 321.1)

135.0 (75.1 to 305.0)

0.2050

 Impaired glucose tolerance (N = 8)

159.6 (131.8 to 208.3)

136.4 (75.5 to 323.1)

0.4948

 Insulin resistance (N = 48)

185.3 (102.1 to 398.2)

132.6 (63.9 to 275.6)

0.0283

FGF19

 Central obesity (N = 116)

160.6 (92.2 to 260.2)

229.4 (119.5 to 345.0)

0.0264

 Low HDL (N = 32)

147.6 (79.4 to 257.8)

194.2 (112.4 to 289.2)

0.1727

 High TG (N = 23)

124.3 (79.3 to 213.8)

184.9 (112.4 to 297.8)

0.0136

 Hypertension (N = 63)

145.7 (93.3 to 244.5)

197.7 (101.1 to 299.7)

0.1085

 Metabolic syndrome (N = 18)

133.0 (62.2 to 171.2)

186.5 (109.2 to 284.7)

0.0509

 Impaired glucose tolerance (N = 8)

86.9 (65.4 to 149.4)

183.8 (106.0 to 289.2)

0.0416

 Insulin resistance (N = 48)

143.0 (81.5 to 229.3)

195.6 (118.2 to 297.8)

0.0233

FGF21

 Central obesity (N = 116)

93.0 (48.8 to 199.5)

70.1 (31.5 to 108.6)

0.0193

 Low HDL (N = 32)

100.3 (48.8 to 165.1)

84.7 (42.1 to 161.0)

0.5064

 High TG (N = 23)

124.6 (78.6 to 363.5)

81.1 (39.5 to 151.3)

0.0035

 Hypertension (N = 63)

124.6 (61.3 to 260.3)

75.2 (39.4 to 115.3)

0.0004

 Metabolic syndrome (N = 18)

136.2 (86.5 to 239.9)

82.6 (41.8 to 152.4)

0.0286

 Impaired glucose tolerance (N = 8)

107.2 (66.2 to 216.8)

86.4 (42.2 to 161.0)

0.4767

 Insulin resistance (N = 48)

91.9 (44.5 to 159.0)

82.6 (42.2 to 161.0)

0.6314

  1. Numbers in first column represent the number of patients with a given clinical condition. The remainder of the group (174-N) were free from these ailments
  2. MS-metabolic syndrome, FGF19 – fibroblast growth factor 19, FGF21 - fibroblast growth factor 21
  3. Significant differences between patients with or without each condition (in columns) were bolded